Timing is everything

Gynecological Endocrinology

Volumn 23, Issue 1, 2007, Pages 1-4

  Genazzani, Andrea Riccardo ^a,b   Simoncini, Tommaso ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTRACEPTION; DEGENERATIVE DISEASE; EDITORIAL; ENDOCRINE FUNCTION; ENDOCRINOLOGY; EVOLUTION; GYNECOLOGY; HEART PROTECTION; HORMONE ACTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; PRIORITY JOURNAL; REPRODUCTION; UNSPECIFIED SIDE EFFECT;

CHRONOBIOLOGY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; REPRODUCTION;

EID: 33847059621     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590601179766     Document Type: Editorial

References (13)

1. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004;291:1701-1712.
3. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
4. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
5. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
6. Stampfer M, Colditz G, Willett W, Manson J, Rosner B, Speizer F, Hennekens C. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
7. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
8. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002;57:357-384.
9. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J Am Med Assoc 2002;288:2123-2129.
10. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-105.
11. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, et al., for the Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 2004;291:2947-2958.
12. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, et al., for the Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-365.
13. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, et al., the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.